All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Agnovos Healthcare, Biostage, Immunexpress, Prisma Health, Quidel, Vero Biotech.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ads Biotec, Atum, Babcock International Group, Cerus, Diazyme Laboratories, Exthera Medical, Grifols, Henry Schein, Ifirst Medical Technologies, Integragen, Ixlayer, Kurabo Industries, Lumos Diagnostics, Microbiosensor, Orthofix, Planet Innovation, Seqster, Suse, Twist Bioscience, Tyto Care, Wittenshein.
The stimulus bill passed by the U.S. Senate March 26 on a vote of 96-0 does more than throw $2.2 trillion into the war against COVID-19. “This is not … a stimulus package. It is emergency relief,” Senate Majority Leader Mitch McConnell (R-Ky.) said on the Senate floor before the vote.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Allovir, APR, Arvelle, Astrazeneca, BMS, Innocoll, Intercept, Jazz, Orphan Technologies, Pear, Recordati, Relief.
Like so many other ventilator providers in recent days, Resmed Inc. has committed to ramping up production. It aims to triple its ventilator output and multiply its ventilation mask production by 10. But the San Diego-based company’s specialty is not mechanical ventilation that requires intubation, which is most commonly used in the intensive care unit (ICU), although it does produce some of those.
The surge of interest in testing for the COVID-19 pathogen has led to some innovative tests and test strategies, including at-home tests. However, the FDA has indicated that it is wary of both at-home testing and specimen collection in other than supervised settings, a policy that is meeting with criticism from some quarters, but not all.
RSS
